指南与共识血栓与止血

ASH活指南:COVID-19重症患者血栓预防抗凝策略2021年5月更新

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.
指南 / 共识 · Blood Adv · 2021-01-01

美国血液学会(ASH)基于GRADE方法制定活指南,针对无确诊或疑似静脉血栓栓塞(VTE)的COVID-19相关重症患者,更新2021年2月版指南。专家组新增1条有条件推荐,支持预防强度优于中等强度抗凝,证据确定性低,强调需更多高质量随机对照试验。

要点

  • 无确诊或疑似VTE的COVID-19重症患者,有条件推荐预防强度而非中等强度抗凝。
  • 该推荐基于低确定性证据,需更多高质量随机对照试验比较不同抗凝强度。
  • 研究重点包括血栓与出血风险预测因素及非抗凝治疗对血栓风险的影响。

核心结论

  • 对无确诊或疑似VTE的COVID-19相关重症患者,ASH有条件推荐预防强度优于中等强度抗凝。

研究设计与样本

  • ASH组建多学科指南专家组(含3名患者代表),由麦克马斯特大学GRADE中心支持,系统证据检索截至2021年3月5日,采用GRADE方法评估证据并形成推荐,经公开评论,为2021年2月版指南的更新。

主要发现

  • 专家组就1条额外推荐达成共识:在无确诊或疑似VTE的COVID-19相关重症患者中,有条件推荐预防强度而非中等强度抗凝。
  • 该推荐基于低确定性证据。

关键数值与推荐

  • 有条件推荐:对无确诊或疑似VTE的COVID-19相关重症患者,预防强度抗凝优于中等强度抗凝。
  • 证据确定性:低。

临床怎么用

  • 对无确诊或疑似VTE的COVID-19相关重症患者,可优先选择预防强度抗凝而非中等强度抗凝。

局限性

  • 推荐基于低确定性证据。
  • 需更多高质量随机对照试验比较不同抗凝强度。
  • 需更好证据关于重症COVID-19患者血栓与出血风险预测因素及非抗凝治疗对血栓风险的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE. METHODS: ASH formed a multidisciplinary guideline panel that included 3 patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process by performing systematic evidence reviews (up to 5 March 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update on guidelines published in February 2021. RESULTS: The panel agreed on 1 additional recommendation. The panel issued a conditional recommendation in favor of prophylactic-intensity over intermediate-intensity anticoagulation in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE. CONCLUSIONS: This recommendation was based on low certainty in the evidence, which underscores the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv. 2021. PMID: 34474482. doi:10.1182/bloodadvances.2021005493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。